Introduction

Asthma is a chronic inflammatory respiratory disease affecting millions of people worldwide. It is characterized by reversible airway obstruction, airway hyperresponsiveness, bronchial inflammation, and mucus hypersecretion. The disease manifests clinically with recurrent episodes of wheezing, coughing, chest tightness, and dyspnea [1-2]. Asthma can occur at any age and significantly affects the quality of life of patients when not properly controlled. The prevalence of asthma has increased globally because of environmental pollution, urbanization, smoking exposure, allergens, occupational hazards, and genetic predisposition. The disease burden is particularly high in children and elderly individuals. Asthma exacerbations contribute to repeated hospitalization, emergency medical visits, reduced work productivity, and increased healthcare costs [3]. Asthma pathogenesis involves chronic inflammation of the airways mediated by eosinophils, mast cells, T-helper-2 lymphocytes, cytokines, leukotrienes, and immunoglobulin E (IgE). Persistent inflammation causes bronchoconstriction, airway edema, mucus secretion, and airway remodeling, leading to impaired airflow and respiratory symptoms. Common triggers include allergens such as dust mites, pollen, animal dander, molds, respiratory tract infections, exercise, cold air, emotional stress, smoke exposure, and certain drugs, including aspirin and beta-blockers. Asthma may be classified as allergic asthma, non-allergic asthma, occupational asthma, exercise-induced asthma, nocturnal asthma, and severe asthma [4]. Diagnosis is based on clinical history, spirometry, peak expiratory flow rate, allergy testing, and pulmonary function assessment. Asthma management focuses on controlling symptoms, preventing exacerbations, maintaining normal lung function, and improving quality of life. Pharmacological treatment includes anti-inflammatory agents, bronchodilators, leukotriene modifiers, methylxanthines, and biologic therapies. Non-pharmacological management includes avoidance of triggers, smoking cessation, vaccination, patient education, and adherence to inhaler therapy.

2. Pathophysiology of Asthma

Asthma is associated with chronic inflammation of the bronchial airways. Inflammatory mediators released by mast cells, eosinophils, macrophages, and T lymphocytes lead to airway edema, mucus hypersecretion, and smooth muscle contraction. Exposure to allergens activates immunoglobulin E-mediated hypersensitivity reactions [5]. This leads to mast cell degranulation and release of histamine, leukotrienes, prostaglandins, and cytokines. These mediators produce bronchoconstriction and airway inflammation. Persistent inflammation results in airway remodeling characterized by smooth muscle hypertrophy, epithelial damage, fibrosis, and thickening of the airway wall. These changes contribute to chronic airflow limitation and severe asthma.

The pathophysiological changes in asthma include:

• Bronchoconstriction
• Airway inflammation
• Mucus hypersecretion
• Airway edema
• Airway remodeling
• Hyperresponsiveness of bronchial smooth muscles

3. Classification of Asthma

Asthma may be classified according to etiology and severity.

• Based on Etiology
• Allergic asthma
• Non-allergic asthma
• Occupational asthma
• Exercise-induced asthma
• Drug-induced asthma
• Nocturnal asthma
  • Based on Severity
• Intermittent asthma
• Mild persistent asthma
• Moderate persistent asthma
• Severe persistent asthma

4. Diagnosis of Asthma

Diagnosis of asthma is based on clinical symptoms, physical examination, and pulmonary function tests.

Diagnostic Methods

• Spirometry
• Peak Expiratory Flow Rate (PEFR)
• Bronchodilator reversibility test
• Allergy testing
• Chest X-ray
• Blood eosinophil count
• Fractional exhaled nitric oxide (FeNO)

Common symptoms include wheezing, cough, chest tightness, shortness of breath, and nocturnal symptoms.

5. Major Categories of Asthma Drugs

5.1. Long-Term Controller Medications: These medications are taken regularly to prevent asthma symptoms and reduce airway inflammation.

5.2. Quick-Relief (Rescue) Medications: These medications provide rapid relief during acute asthma attacks.

5.3 Allergy-Related Treatments in Asthma Management: Medications and therapies used to prevent, relieve, or manage allergic reactions and associated asthma symptoms.

5.4. Biologic Therapies for Severe Asthma: Targeted medications that block specific immune pathways involved in severe asthma to reduce inflammation and asthma attacks.

6. Revised Classification of Asthma Drugs

6.1. Anti-Inflammatory Controller Drugs: These drugs reduce chronic airway inflammation and prevent asthma exacerbations.

6.2. Bronchodilator Drugs: These drugs relax bronchial smooth muscles and improve airflow.

6.3. Combination Therapy: Combination inhalers improve compliance and therapeutic efficacy.

6.4. Target-Specific Monoclonal Antibodies in Severe Asthma Therapy: These biologic therapies selectively target inflammatory mediators involved in severe uncontrolled asthma and are particularly beneficial in eosinophilic and type-2 inflammatory asthma phenotypes.

6.5 Supportive Therapies for Allergic Asthma and Allergic Rhinitis: These supportive therapies are commonly used to control allergic manifestations associated with asthma, improve airway comfort, and reduce exposure-related respiratory symptoms.

7. Newly Approved and Emerging Asthma Drugs

8. Commonly Used Asthma Medications and Their Clinical Significance

 

9. Safety and Efficacy of Asthma Medications

The efficacy of asthma medications depends on their ability to reduce airway inflammation, relieve bronchoconstriction, prevent exacerbations, and improve pulmonary function. Inhaled corticosteroids remain the cornerstone of long-term asthma management because of their strong anti-inflammatory effects and proven efficacy in reducing asthma-related morbidity and mortality [6]. Short-acting beta-agonists provide rapid symptom relief during acute asthma attacks and are highly effective as rescue medications. However, excessive dependence on rescue inhalers may indicate poorly controlled asthma and an increased risk of exacerbations [7]. Combination therapy with ICS and LABAs has demonstrated superior efficacy compared to monotherapy in moderate to severe persistent asthma. LABAs should never be used alone because monotherapy may increase the risk of severe asthma-related complications. Leukotriene modifiers are particularly useful in patients with allergic asthma or exercise-induced bronchospasm, although neuropsychiatric adverse effects require careful monitoring. Theophylline has bronchodilator effects but is less commonly used because of its narrow therapeutic index and risk of toxicity. Biologic therapies have significantly improved outcomes in patients with severe, uncontrolled asthma by targeting specific inflammatory pathways, including IgE, IL-5, IL-4, IL-13, and TSLP. Although highly effective, these therapies are expensive and require administration under medical supervision because of possible hypersensitivity reactions [8-20], asthma medications are considered safe and effective when prescribed appropriately, used with proper inhaler technique, and monitored regularly.

10. Important Safety Measures in Asthma Therapy

• Use inhalers with correct technique.
• Rinse the mouth after corticosteroid inhalation to prevent oral candidiasis.
• LABAs should never be used alone in asthma treatment.
• Frequent rescue inhaler use indicates poorly controlled asthma.
• Avoid prolonged use of nasal decongestant sprays (>3–5 days).
• Monitor theophylline blood levels regularly.
• Biologic therapies should be administered under medical supervision.
• Follow prescribed dosing schedules consistently.
• Maintain regular follow-up and symptom monitoring.

Conclusion

Asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and recurrent respiratory symptoms. Proper diagnosis, identification of triggers, and appropriate pharmacological management are essential for achieving effective asthma control.

Inhaled corticosteroids remain the cornerstone of long-term asthma therapy because of their proven efficacy in reducing airway inflammation and preventing exacerbations. Rescue medications such as short-acting beta-agonists provide rapid symptom relief during acute attacks, while combination therapies and biologic agents improve outcomes in moderate to severe asthma. Allergy-directed therapies are also beneficial in patients with allergic asthma. The safety and effectiveness of asthma medications depend on appropriate drug selection, adherence to therapy, correct inhaler technique, and regular monitoring for adverse effects. Patient education, trigger avoidance, and individualized treatment plans play vital roles in minimizing complications and improving quality of life. With proper management and continuous follow-up, most patients with asthma can achieve good symptom control and lead healthy, active lives.

Modern asthma pharmacotherapy has evolved significantly from conventional bronchodilators to targeted biologic therapies. Advances in biologic agents such as omalizumab, dupilumab, and tezepelumab have transformed the management of severe asthma and improved clinical outcomes in patients with refractory disease.

 

Abbreviations

 

References

 

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update.
2. World Health Organization (WHO). Asthma. World Health Organization Fact Sheets. 2024.
3. National Heart, Lung, and Blood Institute (NHLBI). Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: NHLBI; 2020.
4. National Institute for Health and Care Excellence (NICE). Asthma: Diagnosis, Monitoring and Chronic Asthma Management. NICE Guideline NG80; 2024.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
6. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison’s Principles of Internal Medicine. 21st ed. New York: McGraw-Hill Education; 2022.
8. Barnes PJ. Inhaled corticosteroids. Pharmaceuticals (Basel). 2010;3(3):514–540.
9. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma strategy 2024: executive summary and rationale for key changes. Eur Respir J. 2024;63(2):2302730.
10. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
11. Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: Phase 3 randomized trial of dupilumab efficacy and safety in uncontrolled asthma. J Allergy Clin Immunol. 2018;142(6):1792–1804.
12. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe uncontrolled asthma. Lancet Respir Med. 2021;9(12):1299–1312.
13. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma. Lancet. 2016;388(10056):2115–2127.
14. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
15. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma. Allergy. 2005;60(3):309–316.
16. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715–1726.
17. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial. Chest. 2006;129(1):15–26.
18. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38(6):872–897.
19. Fahy JV. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65.
20. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373.